SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System - Drug-eluting coronary artery stent, biodegradable-polymer-coated

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Commercializzato da:

Boston Scientific Pty Ltd

Classe:

Class III

Prodotto da:

Boston Scientific Corporation 300 Boston Scientific Way, Marlborough, MA, 01752 United States Of America

Area terapeutica:

58771 - Drug-eluting coronary artery stent, biodegradable-polymer-coated

Indicazioni terapeutiche:

The SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System is mounted on a balloon expandable delivery catheter, is inserted percutaneously and advanced through the vasculature to the site of the lesion. The balloon is then inflated to expand the stent to the appropriate diameter. Finally, the balloon is deflated and the balloon catheter removed, leaving the stent in position. The SYNERGY Stent System is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease, including patients with acute myocardial infarction, due to discrete de novo native coronary artery lesions. This device is MR conditional.

Stato dell'autorizzazione:

A

Data dell'autorizzazione:

2014-02-21